PCM
PGNX

Piermont Capital Management’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Piermont Capital Management’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-355,389
Closed -$1.55M – 298
2016
Q1 		$1.55M Sell
355,389
-8,160
-2% -$36.3K 0.49% 92
2015
Q4 		$2.23M Hold
363,549
– – 0.71% 67
2015
Q3 		$2.08M Buy
363,549
+12,855
+4% +$98.6K 0.68% 78
2015
Q2 		$2.62M Buy
+350,694
New +$2.12M 0.79% 63

Other funds holding PGNX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Piermont Capital Management's PGNX Position: Q2 2016 in Review

Piermont Capital Management sold out of Progenics Pharmaceuticals Inc (PGNX) in Q2 2016, closing a stake of 355,389 shares — an estimated $1.55M sold.

Piermont Capital Management first reported a position in PGNX in Q2 2015 and held it in 4 quarters. The position peaked at $2.62M in Q2 2015. 104 funds tracked by Wall St. Rank hold PGNX as of Q2 2016.

  • Piermont Capital Management reported no remaining Progenics Pharmaceuticals Inc position as of Q2 2016 after selling out during the quarter.
  • Piermont Capital Management sold 355,389 Progenics Pharmaceuticals Inc shares in Q2 2016, an estimated $1.55M.
  • Piermont Capital Management first reported a position in Progenics Pharmaceuticals Inc in Q2 2015 and held it in 4 quarters.
  • Piermont Capital Management's Progenics Pharmaceuticals Inc position peaked at $2.62M in Q2 2015.
  • 104 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q2 2016.

Based on Piermont Capital Management's 13F filing for Q2 2016, filed 12 Aug 2016.